Last reviewed · How we verify
NCT00003891
Lurtotecan Liposome in Treating Patients With Advanced Solid Tumors
Phase 1 trial testing lurtotecan liposome in Unspecified Adult Solid Tumor, Protocol Specific in 37 participants. Completed in 22 September 2008.
8 June 2001
Quick facts
| Lead sponsor | NCIC Clinical Trials Group |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 37 |
| Start date | 25 February 1999 |
| Primary completion | 8 June 2001 |
| Estimated completion | 22 September 2008 |
| Sites | 2 locations across Canada |
Drugs / interventions tested
- lurtotecan liposome — full drug profile →
Conditions studied
- Unspecified Adult Solid Tumor, Protocol Specific — all drugs for Unspecified Adult Solid Tumor, Protocol Specific →
Sponsor
NCIC Clinical Trials Group
Who can join
Adults 18 to 120, any sex, with Unspecified Adult Solid Tumor, Protocol Specific. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of lurtotecan liposome in treating patients who have advanced solid tumors.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Cancer Drug Development of Carbonic Anhydrase Inhibitors beyond the Active Site.
Singh S, Lomelino CL, Mboge MY, Frost SC, et al · · 2018 · cited 100× · PMID 29710858 · DOI 10.3390/molecules23051045
Verify or expand the search:
- PubMed search for NCT00003891
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of lurtotecan liposome
Trials testing the same drug.
- NCT00010179 — Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer · Phase 2 · completed
- NCT00006036 — Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors · Phase 1 · completed
Other recruiting trials for Unspecified Adult Solid Tumor, Protocol Specific
Currently open trials in the same condition.
- NCT02112565 — RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Stand · Phase 1 · active not recruiting
- NCT02293954 — Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer · NA · active not recruiting
- NCT00477958 — Assessment Tool for Older Patients With Cancer · NA · active not recruiting
Other NCIC Clinical Trials Group trials
Trials by the same sponsor.
- NCT01916187 — Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma · Phase 1 · withdrawn
- NCT01830621 — BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma · Phase 3 · completed
- NCT01652144 — A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma · Phase 2 · completed
- NCT01627054 — A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia · Phase 2 · completed
- NCT01486368 — A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00003891 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NCIC Clinical Trials Group
- Last refreshed: 9 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00003891.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing